Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.
J Clin Aesthet Dermatol. 2019;12(10):16–23 by Linda Stein Gold, MD; Sunil Dhawan, MD; Jonathan Weiss, MD; Zoe Diana Draelos, MD; Herman Ellman, MD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Dhawan is with the Center for Dermatology Clinical Research, Inc., in Fremont, California. Dr. Weiss
J Clin Aesthet Dermatol. 2019;12(10):45–48 by Jeave Reserva, MD; William Adams, PhD; David Perlman, BS; Brooke Vasicek, MD; Cara Joyce, PhD; Rebecca Tung, MD; and James Swan, MD Drs. Reserva, Vasicek, Tung, and Swan are with the Division of Dermatology at Loyola University Chicago in Chicago, Illinois. Mr. Perlman is with the Stritch School of Medicine
by Srinivas Sidgiddi, MD; Kent Allenby, MD; Franklin Okumu, PhD; and Anirudh Gautam, MPharm Drs. Sidgiddi, Allenby, and Okumu are with Promius Pharma in Princeton, New Jersey. Mr. Gautam is with Dr. Reddy’s Laboratories SA in Basel, Switzerland. FUNDING: This study was funded and sponsored by Dr. Reddy’s Laboratories (DRL #841). DISCLOSURES: Dr. Sidgiddi, MD
by Alexis B. Lyons, MD; Lauren Moy, MD; Ronald Moy, MD; and Rebecca Tung, MD Dr. Lyons is with the Department of Dermatology at Henry Ford Hospital in Detroit, Michigan. Drs. L. Moy and Tung are with the Department of Dermatology at Loyola University Medical Center in Chicago, Illinois. Dr. R. Moy is with Moy,